Circulating CD137<sup>+</sup> T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients

Circulating CD137<sup>+</sup> T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients

Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from immunotherapy, which highlights the need to identify novel biomarkers to optimize treatme...

Full description

Bibliographic Details
Main Authors: Alessio Cirillo, Ilaria Grazia Zizzari, Andrea Botticelli, Lidia Strigari, Hassan Rahimi, Simone Scagnoli, Fabio Scirocchi, Angelina Pernazza, Angelica Pace, Bruna Cerbelli, Giulia d’Amati, Paolo Marchetti, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:International Journal of Molecular Sciences
Subjects:
immunotherapy
anti-PD1
HNSCC
CD137
4-1BB
Online Access:https://www.mdpi.com/1422-0067/24/8/7114

Similar Items

Similar Items